Ocular Therapeutix (OCUL) Reaches $6.55 After 3.00% Up Move, GNC Holdings (GNC) Has 0.75 Sentiment

July 26, 2017 - By Kurt Siggers

GNC Holdings, Inc. is a specialty retailer of health, wellness and performance products, which include protein, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty, food and drink and other general merchandise. The company has market cap of $676.00 million. The Company’s activities consist of purchasing raw materials, formulating and manufacturing products and selling the finished products. It currently has negative earnings. It operates in three divisions: U.S. and Canada, International and Manufacturing/Wholesale.

The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) is a huge mover today! About 164,102 shares traded. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 9.50% since July 26, 2016 and is downtrending. It has underperformed by 26.20% the S&P500.The move comes after 9 months positive chart setup for the $184.67 million company. It was reported on Jul, 26 by Barchart.com. We have $6.75 PT which if reached, will make NASDAQ:OCUL worth $5.54M more.

Healthinvest Partners Ab holds 4.3% of its portfolio in GNC Holdings Inc for 422,955 shares. Fuller & Thaler Asset Management Inc. owns 3.34 million shares or 0.56% of their US portfolio. Moreover, Quinn Opportunity Partners Llc has 0.28% invested in the company for 83,464 shares. The United Kingdom-based Impax Asset Management Ltd has invested 0.26% in the stock. Capital Investment Counsel Inc, a North Carolina-based fund reported 32,775 shares.

Analysts await GNC Holdings Inc (NYSE:GNC) to report earnings on July, 27 before the open. They expect $0.39 EPS, down 50.63% or $0.40 from last year’s $0.79 per share. GNC’s profit will be $28.20 million for 5.99 P/E if the $0.39 EPS becomes a reality. After $0.37 actual EPS reported by GNC Holdings Inc for the previous quarter, Wall Street now forecasts 5.41% EPS growth.

About 390,912 shares traded. GNC Holdings Inc (GNC) has declined 70.69% since July 26, 2016 and is downtrending. It has underperformed by 87.39% the S&P500.

Ratings analysis reveals 0 of GNC Holdings’s analysts are positive. Out of 5 Wall Street analysts rating GNC Holdings, 0 give it “Buy”, 3 “Sell” rating, while 2 recommend “Hold”. The lowest target is $16.0 while the high is $21.0. The stock’s average target of $18.50 is 97.86% above today’s ($9.35) share price. GNC was included in 5 notes of analysts from September 23, 2016. Piper Jaffray downgraded GNC Holdings Inc (NYSE:GNC) on Friday, October 28 to “Underweight” rating. The firm has “Underperform” rating by Bank of America given on Friday, October 28. The stock of GNC Holdings Inc (NYSE:GNC) earned “Sell” rating by Goldman Sachs on Thursday, January 19. The rating was maintained by Deutsche Bank on Friday, October 28 with “Hold”. Barclays Capital initiated GNC Holdings Inc (NYSE:GNC) rating on Friday, September 23. Barclays Capital has “Equal Weight” rating and $21.0 target.

Since January 1, 0001, it had 9 buys, and 0 insider sales for $9.05 million activity.

Ocular Therapeutix, Inc. is a biopharmaceutical company. The company has market cap of $184.67 million. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. It currently has negative earnings. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Analysts await Ocular Therapeutix Inc (NASDAQ:OCUL) to report earnings on August, 8. They expect $-0.64 earnings per share, down 39.13% or $0.18 from last year’s $-0.46 per share. After $-0.58 actual earnings per share reported by Ocular Therapeutix Inc for the previous quarter, Wall Street now forecasts 10.34% negative EPS growth.